Humana Inc. (NYSE:HUM) Shares Sold by Invesco LLC

Invesco LLC decreased its stake in shares of Humana Inc. (NYSE:HUM) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,294 shares of the insurance provider’s stock after selling 119 shares during the period. Invesco LLC’s holdings in Humana were worth $1,089,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in HUM. Atlas Brown Inc. raised its stake in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after purchasing an additional 38 shares during the last quarter. Moors & Cabot Inc. lifted its stake in shares of Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares during the period. OLD National Bancorp IN boosted its position in Humana by 1.8% during the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after acquiring an additional 45 shares during the last quarter. Your Advocates Ltd. LLP grew its stake in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. Finally, Brooklyn Investment Group raised its holdings in Humana by 6.7% in the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after acquiring an additional 46 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.32% of the stock is currently owned by corporate insiders.

Humana Stock Up 0.1 %

Shares of NYSE:HUM traded up $0.24 during midday trading on Wednesday, reaching $303.35. The company had a trading volume of 140,454 shares, compared to its average volume of 1,490,794. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $36.53 billion, a P/E ratio of 26.90, a PEG ratio of 2.15 and a beta of 0.55. The stock’s fifty day moving average price is $275.44 and its 200-day moving average price is $303.14.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts expect that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HUM. KeyCorp initiated coverage on Humana in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. Leerink Partnrs cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. UBS Group dropped their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Royal Bank of Canada decreased their price target on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Piper Sandler boosted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $297.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.